SCHOFIELD, Wis., Feb. 26, 2013 /PRNewswire/ -- PuraMed BioScience®, Inc., (OTCBB: PMBS), a publically traded company engaging in the research, development, and marketing of non-prescription medicinal and healthcare products, has engaged FOCUS LLC, an investment banking firm headquartered in Washington, DC, to explore strategic options for its patented migraine relief product, LipiGesic® M.
FOCUS LLC provides a wide range of finance services to meet the needs of emerging growth and middle market businesses, which it has done since 1982. FOCUS has begun the exploration process and has been in contact with numerous entities that have the potential to support and accelerate the growth of PuraMed BioScience.
"This business relationship with FOCUS gives PuraMed BioScience access to unique resources, processes, and perspectives to explore strategic alternatives to maximize sales and increase shareholder value," said Russell Mitchell, chairman and CEO.
LipiGesic M is a patented, over-the-counter formulation of feverfew and ginger delivered in a sublingual (under-the-tongue), non-aqueous gel that has been clinically studied and recommended as an effective first-line treatment of acute migraine, as published in the June 2011 issue of the top-tier medical journal, Headache: The Journal of Head and Face Pain. LipiGesic M is currently available over-the-counter at Walgreens and CVS/pharmacy stores.
About PuraMed BioScience®, Inc.:
PuraMed BioScience®, Inc., engages in the research, development, and marketing of non-prescription medicinal and healthcare products. PuraMed has completed a double-blind, placebo-controlled clinical trial for its leading product, LipiGesic® M, a sublingual, acute treatment for the relief of migraine headaches.
LipiGesic M has achieved national distribution in some of the largest chain drug stores in the United States. In addition to LipiGesic M, PuraMed BioScience also has plans to launch LipiGesic H, a remedy for tension-type headaches, as well as LipiGesic PM, a remedy for insomnia and other sleep disorders.
This news release contains forward-looking statements regarding PuraMed BioScience, Inc., and its future business plans, which statements involve known and unknown risks and uncertainties. Such risks and uncertainties may cause actual results and future achievements of PuraMed BioScience to be materially different from those implied by these forward-looking statements. PuraMed BioScience has and undertakes no obligation to provide public updates and revisions to these forward-looking statements to reflect any changes in its expectations of future events.
SOURCE PuraMed BioScience, Inc.